Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Piqray / Vijoice (alpelisib by Year
Piqray / Vijoice (alpelisib — PIK3CA-mutated breast cancer & PROS syndrome) ($M)
Novartis Piqray / Vijoice (alpelisib: $382M in FY2025, down 14.9% from a year earlier.
Latest, FY2025
382
Period ended Dec 31, 2025
Change on a year earlier
-14.9%
449 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Piqray/Vijoice | 382 | 449 | -15 | -15”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Piqray / Vijoice (alpelisib — PIK3CA-mutated breast cancer & PROS syndrome) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 382 | -14.9% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 449 | -11.1% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 505 | +35.4% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 373 | +13.4% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 329 | +2.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 320 | +175.9% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 116 | – | Novartis Form 6-K (0001370368-21-000008) ↗ |
Breakdown
What makes up piqray / Vijoice (alpelisib
Cite this data
StockData. (2026). Novartis Piqray / Vijoice (alpelisib ($M), annual FY2019–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-piqray-vijoice
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.